<DOC>
	<DOCNO>NCT00349193</DOCNO>
	<brief_summary>Teva develop laquinimod tablet new oral treatment MS. Laquinimod immunomodulating property . In previous clinical study laquinimod show evidence biological activity reduce number acute brain lesion . The duration current study 36 week .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness , Tolerability Safety Laquinimod</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>1 . Willing able give write informed consent 2 . Confirmed MS diagnosis define McDonald criterion 3 . RR MS disease course . 4 . At least one gadoliniumenhanced lesion screen MRI 5 . Women childbearing potential must practice reliable method birth control . 6 . Must understand requirement study agree comply study protocol . 1 . Subjects suffer form progressive MS. 2 . Any condition investigator feel may interfere participation study . 3 . Subjects clinically significant unstable medical surgical condition would preclude safe complete study participation , 4 . Subjects receive investigational medication , immunosuppressives cytotoxic agent within 6 month prior screen 5 . Previous treatment immunomodulators within two month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
</DOC>